Early Transition to Oral Antimicrobial Therapy Among Children With Staphylococcus aureus Bacteremia and Acute Hematogenous Osteomyelitis: ERRATUM

In the article, “Early Transition to Oral Antimicrobial Therapy Among Children with Staphylococcus aureus Bacteremia and Acute Hematogenous Osteomyelitis” that appeared on pages 690–695 of the September 2022 issue of The Pediatric Infectious Disease Journal, was originally published, inadvertently omitting Table 4, which can be found below.

TABLE 4. - Comparison of Severity of Illness Cohorts Based on Short- and Intermediate-term Outcome Measures Mild (0–3) Moderate (4–7) Severe (8–10) P Inpatient hospital LOS (d), median (IQR) 4.8 (3.8–5.8) 7.4 (5.6–10.7) 16.4 (11.5–24.4) <0.001 ICU LOS (d), median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 2.0 (0.0–7.3) <0.001 Bacteremia (d), median (IQR) 1.0 (1.0–2.0) 2.0 (1.0–3.0) 4.0 (2.0–6.0) <0.001 Duration of IV Abx (d), median (IQR) 3.6 (3.0–5.4) 6.5 (4.6–10.5) 14.3 (11.0–29.8) <0.001 Total Abx duration (d), median (IQR) 34.5 (30.9–45.6) 44.7 (34.3–67.6) 60.7 (44.6–130.4) <0.001 Readmission, n (%) 6 (7.5) 2 (2.0) 18 (26.5) <0.001 Treatment failure*, n (%) 0 (0.0) 5 (5.1) 10 (14.7) <0.001

*Treatment failure is defined as recurrence of infection requiring additional Abx therapy or surgery after discharge, chronic osteomyelitis or recrudescence of bacteremia.

ABX indicates antibiotics; ANOVA, analysis of variance; ICU, intensive care unit; IV, intravenous; IQR, interquartile range.

P value is based on 1-way ANOVA followed by Tukey test for multiple comparisons. Nonparametric testing was conducted with the Kruskal-Wallis method for 3 group comparisons. P value is based on Fisher exact test.


Sanchez MJ, Patel K, Lindsay EA, et al. Early transition to oral antimicrobial therapy among children with staphylococcus aureus bacteremia and acute hematogenous osteomyelitis. Pediatr Infect Dis J. 2020;41:690–695.

留言 (0)

沒有登入
gif